amoxicillin trihydrate and clavulanate potassium powder
shandong new time pharmaceutical co., ltd. - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) -
amoxicillin and clavulanate potassium tablet, film coated
rebel distributors corp. - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 500 mg - amoxicillin and clavulanate potassium tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . caused by β-lactamase-producing strains of s. aureus , e. coli , and klebsiella spp. caused by β-lactamase-producing strains of e. coli , klebsiella spp., and enterobacter spp. while amoxicillin and clavulanate potassium tablets are indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium tablets due to their amoxicillin content; therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase-producing organisms susceptible to amoxicillin and clavulanate po
amoxicillin and clavulanate potassium suspension
rebel distributors corp. - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 600 mg in 5 ml - amoxicillin and clavulanate potassium for oral suspension usp, 600 mg/5 ml is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics ≤ 2 mcg/ml), h. influenzae (including β-lactamase-producing strains), or m. catarrhalis (including β-lactamase-producing strains) characterized by the following risk factors: • antibiotic exposure for acute otitis media within the preceding 3 months, and either of the following: [see clinical pharmacology, microbiology .] note: acute otitis media due to s. pneumoniae alone can be treated with amoxicillin. amoxicillin and clavulanate potassium for oral suspension is not indicated for the treatment of acute otitis media due to s. pneumoniae with penicillin mic ≥ 4 mcg /ml. therapy may be instituted prior to obtaining the results from bacteriological studies when there is reason to believe the infection may involve both s. pneumoniae (penicillin mic ≤ 2 mcg/ml) and the β-lactamase-producing orga
amoxicillin and clavulanate potassium- amoxicillin and clavulanate potassium tablet, film coated
state of florida doh central pharmacy - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 875 mg - amoxicillin/clavulanate potassium is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: lower respiratory tract infections - caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis. otitis media - caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis. sinusitis - caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis. skin and skin structure infections - caused by β-lactamase-producing strains of s. aureus, e. coli and klebsiella spp. urinary tract infections - caused by β-lactamase-producing strains of e. coli , klebsiella spp. and enterobacter spp. while amoxicillin/clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to amoxicillin/clavulanate potassium treatment due to its amoxicillin content, therefore, mixed infections caused by ampicillin-susceptible orga
amoxicillin and clavulanate potassium powder, for suspension
rebel distributors corp. - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 400 mg in 5 ml - amoxicillin and clavulanate potassium for oral suspension and chewable tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: lower respiratory tract infections – caused by β-lactamaseproducing strains of h. influenzae and m. catarrhalis. otitis media – caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis. sinusitis – caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis. skin and skin structure infections – caused by β-lactamaseproducing strains of s. aureus, e. coli and klebsiella spp. urinary tract infections – caused by β-lactamase-producing strains of e. coli, klebsiella spp. and enterobacter spp. while amoxicillin and clavulanate potassium for oral suspension and chewable tablets are indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to amoxicillin and clavulanate potassium for oral suspensi
amoxicillin and clavulanate potassium powder, for suspension
physicians total care, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 200 mg in 5 ml - amoxicillin and clavulanate potassium for oral suspension and chewable tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: lower respiratory tract infections – caused by β-lactamaseproducing strains of h. influenzae and m. catarrhalis. otitis media – caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis. sinusitis – caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis. skin and skin structure infections – caused by β-lactamaseproducing strains of s. aureus, e. coli and klebsiella spp. urinary tract infections – caused by β-lactamase-producing strains of e. coli, klebsiella spp. and enterobacter spp. while amoxicillin and clavulanate potassium for oral suspension and chewable tablets are indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to amoxicillin and clavulanate potassium for
amoxicillin and clavulanate potassium tablet, chewable
physicians total care, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 400 mg - amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: lower respiratory tract infections - caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . otitis media - caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . sinusitis - caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . skin and skin structure infections - caused by β-lactamase-producing strains of s. aureus , e. coli , and klebsiella spp. urinary tract infections - caused by β-lactamase-producing strains of e. coli , klebsiella spp. and enterobacter spp. while amoxicillin and clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate
amoxicillin and clavulanate potassium- amoxicillin and clavulanate potassium powder, for suspension amoxicillin and clavulanate
ranbaxy pharmaceuticals inc. - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - powder, for suspension - 200 mg in 5 ml - amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: lower respiratory tract infections - caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . otitis media - caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . sinusitis - caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . skin and skin structure infections - caused by β-lactamase-producing strains of s. aureus , e. coli , and klebsiella spp. urinary tract infections - caused by β-lactamase-producing strains of e. coli , klebsiella spp. and enterobacter spp. while amoxicillin and clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium due
amoxicillin and clavulanate potassium tablet, film coated
state of florida doh central pharmacy - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin and clavulanate potassium tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: lower respiratory tract infections – caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . otitis media – caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . sinusitis – caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . skin and skin structure infections – caused by β-lactamase-producing strains of s. aureus , e. coli, and klebsiella spp. urinary tract infections – caused by β-lactamase-producing strains of e. coli , klebsiella spp., and enterobacter spp. while amoxicillin and clavulanate potassium tablets are indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium tablets due to its amoxicillin content; therefore, mi
amoxicillin and clavulanate potassium tablet, film coated
state of florida doh central pharmacy - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin and clavulanate potassium tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . caused by β-lactamase-producing strains of s. aureus , e. coli , and klebsiella spp. caused by β-lactamase-producing strains of e. coli , klebsiella spp., and enterobacter spp. while amoxicillin and clavulanate potassium tablets are indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium tablets due to their amoxicillin content; therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase-producing organisms susceptible to amoxicillin and clavulanate po